Brand-name pharmaceutical companies and health insurers increased their profits in the second quarter of this year, while hospitals and drug distributors had a more difficult run, according to a review of financial documents for 58 publicly traded health care companies.

Between the lines: Drug companies continue to raise their list prices for branded drugs despite the public furor, so they naturally maintained their status as the most profitable sector in health care. Insurers also collected higher profits because fewer people are going to the hospital or doctor, which results in more money staying in their pockets.